Pimjetmi FDA Approval: Third CSF-1R Drug for TGCT Arrives With Once-Daily Dosing
FDA approves Pimjetmi (pimicotinib), a once-daily CSF-1R inhibitor for tenosynovial giant cell tumor, after a 54% vs 3% response in Phase 3 MANEUVER. How it stacks up.
Tag: Abbisko Therapeutics
Read More